Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

Gossamer Bio

06/05/2024 12:41

May 6 (Reuters) - Gossamer Bio  GOSS.O  said on Monday
it will collaborate with Chiesi Group to develop and
commercialize its drug seralutinib in multiple indications
related to blood pressure conditions.
    Gossamer is to receive $160 million development
reimbursement payment and is eligible to receive up to $146
million in regulatory and $180 million in sales milestones as
part of the deal. 

 (Reporting by Christy Santhosh; Editing by Vijay Kishore)
 ((Christy.Santhosh@thomsonreuters.com;))